Using the molecular classification of glioblastoma to inform personalized treatment
Использование молекулярной классификации глиобластомы для информирования персонализированного лечения
2013-10-11
SCID: 54.1/yppw7yku
Discuss with AI
genetic and gene-expression heterogeneityglioblastomamolecular classificationtargeted drug developmenttreatment resistance and recurrence
Figures from the paper
Abstract (AI)
Glioblastoma is the most common and most aggressive diffuse glioma, associated with short survival and uniformly fatal outcome, irrespective of treatment. It is characterized by morphological, genetic and gene-expression heterogeneity. The current standard of treatment is maximal surgical resection, followed by radiation, with concurrent and adjuvant chemotherapy. Due to the heterogeneity, most tumours develop resistance to treatment and shortly recur. Following recurrence, glioblastoma is quickly fatal in the majority of cases. Recent genetic molecular advances have contributed to a better understanding of glioblastoma pathophysiology and disease stratification. In this paper we review basic glioblastoma pathophysiology, with emphasis on clinically relevant genetic molecular alterations and potential targets for further drug development.
Key Findings
1
Clinically relevant genetic molecular alterations identified offer potential targets for future drug development and personalized treatment approaches.
2
Glioblastoma exhibits morphological, genetic, and gene-expression heterogeneity that drives treatment resistance and rapid recurrence.
3
Glioblastoma is the most common and aggressive diffuse glioma with short survival and uniformly fatal outcomes despite treatment.
4
Recent genetic and molecular advances have improved understanding of glioblastoma pathophysiology and enabled disease stratification.
5
Standard treatment—maximal surgical resection followed by radiation with concurrent and adjuvant chemotherapy—does not prevent near-universal recurrence and poor prognosis.
Research Object
Glioblastoma tumors
Research Subject
Clinically relevant genetic/molecular alterations and their use in molecular classification to inform personalized treatment targets and drug development
Publication Details
Publication Date
2013-10-11
Journal
Publisher
ISSN
Cited by
278
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
An Integrated Genomic Analysis of Human Glioblastoma Multiforme2008
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-20092012
Genetic Pathways to Glioblastoma2004
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas2012